Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
Provide signed written informed consent and voluntarily agree to participate in this study.
Age ≥ 18 years and ≤ 75 years.
Histologically confirmed colorectal adenocarcinoma.
Liver metastasis confirmed by imaging or pathology.
Have a history of allergy to monoclonal antibodies, any component of retlirafusp alfa, bevacizumab, capecitabine, oxaliplatin, or other platinum-based agents.
Any anti-tumor therapy including surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 2 weeks prior to the first dose of study drug (at a dose > 10 mg/day prednisone or equivalent). Inhaled or topical corticosteroids, and adrenal replacement therapy at doses > 10 mg/day prednisone or equivalent, are permitted in the absence of active autoimmune disease.
Receipt of live attenuated vaccine within 4 weeks prior to the first dose of study drug.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborator